

# [FeFe]-Hydrogenase Oxygen Inactivation Is Initiated at the H Cluster 2Fe Subcluster


Kevin D. Swanson,<sup>†,§</sup> Michael W. Ratzloff,<sup>‡,§</sup> David W. Mulder,<sup>‡</sup> Jacob H. Artz,<sup>†</sup> Shourjo Ghose,<sup>†</sup> Andrew Hoffman,<sup>†</sup> Spencer White,<sup>†</sup> Oleg A. Zadovnyy,<sup>†</sup> Joan B. Broderick,<sup>†</sup> Brian Bothner,<sup>†</sup> Paul W. King,<sup>\*,‡</sup> and John W. Peters<sup>\*,†</sup>

<sup>†</sup>Department of Chemistry and Biochemistry, Montana State University, Bozeman, Montana 59717, United States

<sup>‡</sup>Biosciences Center, National Renewable Energy Laboratory, Golden, Colorado 80401, United States

## Supporting Information


**ABSTRACT:** The [FeFe]-hydrogenase catalytic site H cluster is a complex iron sulfur cofactor that is sensitive to oxygen (O<sub>2</sub>). The O<sub>2</sub> sensitivity is a significant barrier for production of hydrogen as an energy source in water-splitting, oxygenic systems. Oxygen reacts directly with the H cluster, which results in rapid enzyme inactivation and eventual degradation. To investigate the progression of O<sub>2</sub>-dependent [FeFe]-hydrogenase inactivation and the process of H cluster degradation, the highly O<sub>2</sub>-sensitive [FeFe]-hydrogenase HydA1 from the green algae *Chlamydomonas reinhardtii* was exposed to defined concentrations of O<sub>2</sub> while monitoring the loss of activity and accompanying changes in H cluster spectroscopic properties. The results indicate that H cluster degradation proceeds through a series of reactions, the extent of which depend on the initial enzyme reduction/oxidation state. The degradation process begins with O<sub>2</sub> interacting and reacting with the 2Fe subcluster, leading to degradation of the 2Fe subcluster and leaving an inactive [4Fe-4S] subcluster state. This final inactive degradation product could be reactivated *in vitro* by incubation with 2Fe subcluster maturation machinery, specifically HydF<sup>EG</sup>, which was observed by recovery of enzyme activity.



## INTRODUCTION

[FeFe]-hydrogenases are found in bacteria and lower eukaryotes and are commonly involved in the recycling of reduced electron carriers that accumulate during anaerobic metabolism.<sup>1</sup> [FeFe]-hydrogenases catalyze reversible H<sub>2</sub> activation at very high rates and thus are attractive targets for bioengineering efforts aimed at coupling microbial H<sub>2</sub> production to oxygenic photosynthesis.<sup>2,3</sup> The proton reduction reaction in [FeFe]-hydrogenases occurs at a complex bridged FeS cluster termed the H cluster.<sup>4,5</sup> The H cluster exists as a regular [4Fe-4S] subcluster bridged to an organometallic, 2Fe subcluster through a protein cysteine thiolate. The 2Fe subcluster is coordinated by unique nonprotein ligands including CO, CN, and dithiomethylamine (Figure 1).<sup>4–8</sup>


A major barrier to utilization of [FeFe]-hydrogenases for photosynthetic H<sub>2</sub> production is they are rapidly inactivated upon exposure to O<sub>2</sub>, the byproduct of water oxidation.<sup>9–11</sup> However, [FeFe]-hydrogenases from different sources vary significantly in the level of sensitivity,<sup>12–16</sup> and understanding the basis for this variation may provide insight into addressing this limitation. One hypothesis to account for the variation is from structural differences controlling the initial access or



**Figure 1.** H cluster ball-and-stick representation with carbon, nitrogen, oxygen, sulfur, and iron atoms colored gray, blue, red, yellow, and orange, respectively (PDB 3C8Y).


Received: October 9, 2014

Published: January 12, 2015



**Figure 2.** FTIR spectra of CrHydA1 samples exposed to O<sub>2</sub>. The solid red spectra are prior to O<sub>2</sub> injection, and black traces after 2 h exposure to O<sub>2</sub> at pH 8, 277 K. (a) H<sub>ox</sub>, ~0.01% O<sub>2</sub>; (b) H<sub>ox</sub>-CO, ~2.4% O<sub>2</sub>; (c) H<sub>red</sub>-H<sub>2</sub>, ~0.01% O<sub>2</sub>; (d) H<sub>red</sub>-NaDT, ~0.05% O<sub>2</sub>. Wavenumbers assignments: H<sub>ox</sub>, red; H<sub>ox</sub>-CO, black; H<sub>red</sub>-NaDT and H<sub>red</sub>-H<sub>2</sub>, green; O<sub>2</sub> damaged, purple; and unassigned, cyan. Additional experimental conditions are described in the Experimental Section.

transport of O<sub>2</sub> to the H cluster.<sup>15,17,18</sup> Support for this comes from computational studies that have revealed putative hydrophobic channels proposed to function in the diffusion of gases, including O<sub>2</sub>, to and from the active site.<sup>17,19</sup> In addition to O<sub>2</sub> access, density functional theory (DFT) has been employed as a means to probe the binding and reaction steps that subsequently result in O<sub>2</sub>-dependent enzyme degradation. Binding models suggest that initiation of O<sub>2</sub> interaction with the H cluster differs between enzymes and is dependent on H cluster oxidation state.<sup>20–22</sup> The O<sub>2</sub> binds at the H cluster distal Fe (Fe<sub>d</sub>) to result in formation of “transient” -OOH or -O<sub>2</sub><sup>-</sup> terminal species. Further reaction



**Figure 3.** Time course of the FTIR spectra of H<sub>ox</sub> CrHydA1 exposed to ~0.01% O<sub>2</sub> at pH 8, 277 K. The initial H<sub>ox</sub> signal (1804, 1940, 1964, 2071, and 2089 cm<sup>-1</sup>) gradually decays, and the spectrum transitions to a characteristic H<sub>ox</sub>-CO signal with  $\nu$ CO peaks at 1809, 1963, 1969, and 2013 cm<sup>-1</sup>. Signals assigned to O<sub>2</sub> damaged clusters are shown in purple. Additional experimental conditions are described in the Experimental Section.

cycles of the terminal “O” species with H<sup>+</sup> generate H<sub>2</sub>O<sub>2</sub> or Fe-peroxide.<sup>21,23</sup>

The computational models of the O<sub>2</sub> inactivation process require further validation but suggest reactions with O<sub>2</sub> are dependent on availability of both protons and electrons.<sup>23,24</sup> Hints at the chemical nature of the O-species produced from O<sub>2</sub> reactions at the H cluster have come from electrochemical studies of O<sub>2</sub> reduction by a 2Fe subcluster model complex. The subcluster was found to reduce O<sub>2</sub> to ROS (i.e., H<sub>2</sub>O<sub>2</sub>) and catalyzed the complete 4e<sup>-</sup> reduction to H<sub>2</sub>O, the extent of which was dependent on pH, potential, and scan rate. The 2Fe

subcluster degradation pathways also included FeS oxidation (e.g., Fe-oxidation and S-oxygenation).<sup>25</sup> These results together with DFT calculations on O<sub>2</sub> products imply that the [FeFe]-hydrogenases might also catalyze the reduction of O<sub>2</sub> as a substrate where differences in proton/electron availability may account for the differences in sensitivity among enzymes.<sup>23,25</sup>

Inactivation of the [FeFe]-hydrogenases has also been studied by electrochemical methods.<sup>13–16,26,27</sup> Aerobic, O<sub>2</sub> inactivation was shown to be a potential-dependent process and that the presence of CO or H<sub>2</sub> affords a protective effect via competitive binding to Fe<sub>d</sub> of the 2Fe subcluster. Anaerobic, oxidative inactivation of [FeFe]-hydrogenases has been observed at potentials >65 mV (vs SHE) in the presence of H<sub>2</sub> and was modeled by DFT to involve reversible and irreversible structural rearrangements of the H<sub>ox</sub> state.<sup>26</sup> Irreversible inactivation occurred at more positive potentials and was modeled as a slow oxidation of H<sub>ox</sub> followed by nucleophilic attack and degradation.<sup>26</sup> Whether aerobic inactivation involves similar redox-induced rearrangements remains to be determined. Structural and biophysical studies on O<sub>2</sub> reactions with the H cluster are challenging, and reports are limited.<sup>13,14</sup> A mechanistic model from X-ray absorption spectroscopy (XAS) studies on CrHydA1 proposes that O<sub>2</sub> reactions with the H cluster produce ROS that results in the initial destruction of the [4Fe-4S] subcluster.<sup>27,28</sup> This model accounts for the protective effect of CO (which prevents O<sub>2</sub> binding at the 2Fe subcluster) but conflicts with conclusions from DFT whereby O<sub>2</sub> reacts with 2Fe subcluster to form ROS or other oxidation products that initially degrade the 2Fe subcluster, not the [4Fe-4S] subcluster.<sup>21,23</sup>

The models that have emerged from computational and experimental studies have led to some controversy as to the nature of O<sub>2</sub>-dependent inactivation of [FeFe]-hydrogenases and mechanism of H cluster degradation.<sup>29</sup> In order to resolve uncertainties on the mechanism of O<sub>2</sub> inactivation of [FeFe]-hydrogenases, we have exposed the [FeFe]-hydrogenase from *Chlamydomonas reinhardtii* (CrHydA1) to different titers of O<sub>2</sub> while monitoring changes in the biochemical activities and Fourier transform infrared (FTIR) and UV–vis spectroscopic properties. The FTIR results indicate that H cluster reacts with O<sub>2</sub> and undergoes a series of reactions to produce a mixture of inactivation intermediates, the populations of which depend on the initial reduction/oxidation state of the H cluster. Ultimately, oxidative destruction results in the loss of the 2Fe subcluster and formation of a [4Fe-4S] subcluster intermediate state. This inactivation/degradation intermediate could be reactivated *in vitro* by incubation with the 2Fe subcluster-specific maturation machinery.

## EXPERIMENTAL SECTION

**Protein Preparation.** Heterologous expression and purification of CrHydA1 in *Escherichia coli* was performed as previously described.<sup>30,31</sup> The protein was purified under anaerobic conditions in an MBraun anaerobic chamber (MBraun USA). All buffers were gas exchanged under repeated cycles of vacuum and O<sub>2</sub>-free gas prior to purification. CrHydA1 isolation from cell extracts was performed using a two-step chromatography process of ion-exchange over diethylaminoethanol (DEAE, GE Lifesciences) Sepharose followed by affinity capture on Strep-Tactin (IBA) resin.<sup>31</sup> Strep-Tactin bound enzyme was eluted in 50 mM Tris buffer (pH 8.0) containing 300 mM NaCl, 5% glycerol, 5 mM sodium dithionite (NaDT), and 2 mM desthiobiotin. Purity was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and the concentration determined by Bradford assay. CrHydA1 was prepared in the

oxidized (H<sub>ox</sub>) state by serial concentration and dilution in NaDT-free buffer until the FTIR spectra consisted primarily of H<sub>ox</sub>.

HydF was obtained by expression of *hydF* in the background of HydE and HydG (HydF<sup>EG</sup>) in *E. coli* strain BL21 (DE3). The *hydE*, *hydF*, and *hydG* from *Clostridium acetobutylicum* were individually cloned into pET-Duet, pRSF-Duet, and pCDF-Duet, respectively.<sup>32</sup> The cloned copy of *hydF* contained a N-terminal 6xHis tag.<sup>32</sup> Cells were grown in LB Miller growth medium supplemented with streptomycin (50 mg L<sup>-1</sup>), kanamycin (30 mg L<sup>-1</sup>), ampicillin (100 mg L<sup>-1</sup>), 0.5% w/v glucose (~25 mM), 2 mM ferric ammonium citrate, and 50 mM phosphate buffer (final pH of medium was 7.4). All cultures were grown aerobically at 25 °C until an OD<sub>600</sub> of 0.5. Cultures were sparged with 100% argon for 20 min and induced with 1.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cysteine (2 mM) and sodium fumarate (25 mM) were added immediately after IPTG addition. For expression under anaerobic conditions, cultures were sparged with argon at 25 °C overnight.

HydF<sup>EG</sup> was purified in an anaerobic chamber (Coy Laboratories, Grass Lake, MI) as previously described.<sup>32</sup> Cells were harvested by centrifugation and cell pellets stored at -80 °C. Cells were lysed by resuspension in buffer composed of 10 mM HEPES, pH 7.4, 0.5 M KCl, 5% glycerol, 1 mM dithiothreitol, 20 mM imidazole, 20 mM MgCl<sub>2</sub>, 1 mM PMSF, 1% Triton X-100, 140 μg mL<sup>-1</sup> DNase and RNase, and 120 μg mL<sup>-1</sup> lysozyme. The cell lysate was stirred for 1 h at room temperature and centrifuged in gastight bottles at 38,000 × g for 30 min. The His-HydF<sup>EG</sup> was purified from the supernatant by immobilized metal chromatography on a TALON cobalt column (GE Life Sciences). The column was loaded and washed with 15 column volumes of 20 mM HEPES pH 7.4, 0.5 M KCl, 5% glycerol, 1 mM dithiothreitol, and 20 mM imidazole. Purified HydF<sup>EG</sup> was eluted with 200 mM imidazole. HydF<sup>EG</sup> was collected and concentrated anaerobically with 30 kDa Amicon Ultra-15 centrifugal concentrators (Millipore). The HydF<sup>EG</sup> was loaded onto a G25 PD-10 desalting column (GE Life Sciences) to remove imidazole and eluted with 50 mM HEPES pH 7.4, 0.5 M KCl, 5% glycerol, and 1 mM dithiothreitol. Purified HydF<sup>EG</sup> was flash frozen in liquid N<sub>2</sub> and stored at -80 °C or in liquid N<sub>2</sub> until further use.

**Preparation of Oxygen Treated CrHydA1.** O<sub>2</sub> gas standards were prepared using septum-sealed 123 mL Wheaton vials. Dilutions were prepared using a gastight syringe (Hamilton) to remove gas from a 100% O<sub>2</sub> standard (equilibrated to atmospheric pressure) and injecting the O<sub>2</sub> into vials containing 100% N<sub>2</sub> at atmospheric pressure. Standards of 100%, 4%, 1%, and 0.1% O<sub>2</sub> were used for all of the O<sub>2</sub> additions. Samples used to measure the FTIR spectra of O<sub>2</sub> treated CrHydA1 were prepared as follows. H<sub>ox</sub> (Figures 2 and 3): O<sub>2</sub> was injected by gastight syringe into the headspace above an 825 μL aliquot of oxidized CrHydA1 at 45 mg mL<sup>-1</sup> in a septum-sealed 825 μL conical vial. CO-inhibited (H<sub>ox</sub>-CO): a 15 μL aliquot of 70 mg mL<sup>-1</sup> H<sub>ox</sub> CrHydA1 was injected via gastight syringe into a septum-sealed 825 μL conical vial that had previously been flushed with 100% CO. O<sub>2</sub> was then injected by gastight syringe into the headspace of the conical vial (Figures 2 and S1). H<sub>2</sub> reduced (H<sub>red</sub>-H<sub>2</sub>) (Figure 2): 70 μL of 30 mg mL<sup>-1</sup> H<sub>ox</sub> CrHydA1 in a septum-sealed 825 μL conical vial, along with three similar empty conical vials, underwent 10 vacuum/100% H<sub>2</sub> exchanges on a Schlenk line and was incubated for 1 h at 4 °C in the MBraun. A 10 μL aliquot of this enzyme sample was transferred to each one of the empty, H<sub>2</sub>-treated vials via gastight syringe. O<sub>2</sub> was then injected by gastight syringe into the headspace of each vial. NaDT-reduced (H<sub>red</sub>-DT) (Figures 2 and S2): in the MBraun glovebox, NaDT (20 mM final) was added to 50 μL of 50 mg mL<sup>-1</sup> H<sub>ox</sub> CrHydA1 (45 mg mL<sup>-1</sup> final) and mixed via pipetting for 30 s. A 15 μL aliquot was transferred to a 825 μL conical vial and then sealed with a septum. O<sub>2</sub> was injected by gastight syringe into the headspace of the conical vials.

In all cases, the conical vials contained a microstir bar and were stirred while on an ice bath. Final O<sub>2</sub> concentrations ranged from 0.01 to 24.7% (v/v). In order to minimize pressure increases due to gas injection, the appropriate standard was used to keep the injection volume <5% of the vial volume (with the exception of the 24.7% CO sample shown in Figure S1). An aliquot of CrHydA1 was removed

from the septum-sealed vial using gastight syringe and loaded in a custom gastight FTIR sample cell.<sup>33</sup> A summary of the O<sub>2</sub> concentration and molar ratios is given in Table S1. Control experiments were performed to estimate the repeatability of O<sub>2</sub> injections, with O<sub>2</sub> concentrations determined by GC (Agilent Technologies). The standard deviation for O<sub>2</sub> injections is estimated to be SD = ±(% O<sub>2</sub> × 0.15) or ±15% of each individual injection (Table S2).

**FTIR Spectroscopy.** Spectra were collected as described previously with a Nicolet 6700 FTIR spectrometer (Thermo Fisher Scientific) equipped with a Globar IR source, a CaF<sub>2</sub> beam splitter, and a liquid-nitrogen-cooled mercury cadmium telluride (MCT) detector.<sup>33</sup> All of the spectra were collected at room temperature (21 °C). The custom-built sample chamber consists of a covered aluminum box designed to minimize external light interference with the sample. The OMNIC software was configured to report absorbance spectra, and absorbance baselines were fit to these data using a manually adjusted spline.

**UV-vis Spectroscopy.** A 100 μL aliquot of 3 mg mL<sup>-1</sup> H<sub>ox</sub> CrHydA1 was prepared in the glovebox under 100% N<sub>2</sub>, transferred into low volume 1 cm path-length quartz cuvette, and septum sealed. The O<sub>2</sub> reaction was initiated by injecting O<sub>2</sub> (at 0.001%, 17%, or 300%) with a gastight syringe into the headspace of cuvette with the enzyme solution at 4 °C, cooled with a Peltier cooler. A microstir bar provided agitation of the solution in the cuvette. The reaction of CrHydA1 with O<sub>2</sub> was monitored by UV-vis every min for 200–300 min, by scanning over a 250–750 nm range at 1 nm intervals. UV-vis spectra were recorded on a Cary 4000 UV-vis spectrophotometer.

**Activity Assays.** Activities of CrHydA1 were assayed by H<sub>2</sub> evolution from reduced methyl viologen. Reaction volumes of 0.6 or 2 mL were placed in 3 or 10 mL Wheaton vials containing 5 mM methyl viologen (MV), 10 mM NaDT, 50 mM Tris, 300 mM NaCl, 5% glycerol, and between 25 ng and 4 μg of enzyme per assay. Hydrogen production was detected by gas chromatography (Agilent Technologies).

**Mass Spectrometry.** Protein digests were performed with 1.5 mg mL<sup>-1</sup> CrHydA1, 12.5 μg mL<sup>-1</sup> Trypsin Gold (Promega), 50 mM Tris-HCl pH 8, 300 mM NaCl, and 5% glycerol. Reactions were incubated overnight in a 37 °C heat block, and complete digestion was verified by SDS-PAGE. The digestion product was diluted up to a 1000-fold in 50/50 water/acetonitrile and transferred to screw capped auto sampler vials for LCMS.

An Agilent 1100 series HPLC system coupled to an Agilent Chip Cube integrated microfluidics reverse-phase nano-HPLC system was used. Trapping and analytical separations were performed with an Agilent C18 HPLC-Chip (G4240-62001, 40 nl trap column and 75 μm × 43 mm analytical). Chromatography solvents were H<sub>2</sub>O with 0.1% (v/v) formic acid for channel “A” and acetonitrile for channel “B”. The HPLC program was held at 7% B from 0.0 to 2.0 min, then ramped from 7 to 35% B from 2.0 to 20.0 min. The gradient was then ramped from 35 to 95% B from 22 to 27 min. The mass spectrometer was an Agilent 6520 Q-TOF with a dual-ESI source: resolution approximately 20,000 and accuracy 3 ppm. Spectra were collected in positive mode from 50 to 1700 m/z at 2 Hz for both MS and MS/MS, with adaptive acquisition time for highly abundant ions.

The resulting MS/MS data were analyzed using the PEAKS 6.0 software package and searching the CrHydA1 protein sequence. Peptide mass tolerance was 10 ppm and fragment mass tolerance 0.5 Da. Variable modifications were set to sulfonic acid 47.97, sulfonic acid 31.98, and oxidation or hydroxylation of cysteine 15.99.

**Crystallization and Structure Determination.** CrHydA1 (1 mL at 10 mg mL<sup>-1</sup>) in NaDT free buffer was exposed to 0.01% O<sub>2</sub> for 2 h in a 4.5 mL Wheaton vial. Enzyme activity was measured at the end of the 2 h period (50 μmol min<sup>-1</sup> mg<sup>-1</sup>). An aliquot of the sample was set aside for trypsin digest and MS analysis, and the rest of the sample was concentrated to 30 mg mL<sup>-1</sup> for crystallization. CrHydA1 was crystallized anaerobically in a MBraun glovebox at room temperature using microcapillary batch diffusion with a precipitation solution of 25.5% polyethylene glycol 8000 as precipitate and 0.085 M sodium cacodylate (pH 6.5), 0.17 M sodium acetate trihydrate, and 1 mM dithionite. After allowing the crystals to form for 2–3 weeks, they were

mounted on cryo-loops and flash frozen in liquid nitrogen. Data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) on beamline BL12-1 at 1.75 Å wavelength. The data was processed using XDS<sup>34</sup> and scaled with Pointless and Aimless.<sup>35</sup> The structure was solved using molecular replacement using AutoMR (CCP4 suite of programs) with CrHydA1 (PDB ID, 3LX4).<sup>36</sup> The structure was built using COOT with further refinement using REFMAC5 using NCS and B factor restraints. The final model was solved to 2.23 Å with an R factor of 24.1% and an R free of 27.7% (Table S5). Atomic coordinates were deposited in the PDB (code 4ROV).

**In vitro Reactivation of O<sub>2</sub> Inactivated CrHydA1.** Reactivation of the O<sub>2</sub> inactivated CrHydA1 was performed with the addition of N-terminal His tagged-HydF<sup>EG</sup> at different molar ratios to obtain a 300 μL total volume in 3 mL crimp sealed anaerobic Wheaton vials. CrHydA1 was allowed to reactivate at 37 °C in a water bath for 1 h, and reactivation was followed by measuring the H<sub>2</sub> production activity as described above.

## RESULTS

**FTIR Analysis and Comparison of Oxidized, Reduced, and CO-Inhibited CrHydA1.** The H cluster oxidation state and 2Fe subcluster site occupancy are known to affect the process of O<sub>2</sub> damage. To test whether FTIR can also detect changes in O<sub>2</sub> damage of the 2Fe subcluster, the reducing agents sodium dithionite (NaDT) and H<sub>2</sub> and the competitive inhibitor CO were each added to oxidized (H<sub>ox</sub>) CrHydA1, and the samples exposed to O<sub>2</sub> and monitored by FTIR. CrHydA1 prepared in the H<sub>ox</sub> state has major peaks at 1804, 1940, 1964, 2071, and 2089 cm<sup>-1</sup> (Figure 2a, red spectrum). Exposure of the H<sub>ox</sub> CrHydA1 to ~0.01% O<sub>2</sub> (Figure 2a, black spectrum) for 2 h resulted in the loss of H<sub>ox</sub> features and an increase in features assigned to CO-inhibited (H<sub>ox</sub>-CO) and O<sub>2</sub>-damaged H cluster. By comparison, a control time-course experiment (Figure S3) on a duplicate CrHydA1 sample in the absence of O<sub>2</sub> showed only slight changes in the intensity of the H<sub>ox</sub> signal, which increased presumably due to auto-oxidation of H<sub>red</sub>.

When H<sub>ox</sub> CrHydA1 was exposed to CO to make H<sub>ox</sub>-CO (Figure 2b, red spectrum), the νCO and νCN peaks shifted to higher wavenumbers (νCO at 1809, 1963, 1969, 2013, and νCN at 2082 and 2091 cm<sup>-1</sup>) as was previously reported for CO-inhibited [FeFe]-hydrogenases.<sup>33,37–39</sup> The enzyme was then exposed to ~2.4% O<sub>2</sub>. H<sub>ox</sub>-CO was exposed to larger percentages of O<sub>2</sub> in order to determine whether attenuation of FTIR signal could be observed. After approximately 2 h of O<sub>2</sub> exposure, the FTIR spectrum indicated the peaks assigned to H<sub>ox</sub>-CO remained relatively unchanged (Figure 2b, red vs black spectrum). Small peaks appeared, which are attributed to degradation of some residual H<sub>ox</sub> species. Enzyme in the H<sub>ox</sub>-CO state was also treated with higher amounts of O<sub>2</sub> (up to ~24.7%, Figure S1), and the resulting FTIR spectrum again showed significantly less degradation compared to H<sub>ox</sub> and H<sub>red</sub> preparations, consistent with previous observations that H<sub>ox</sub>-CO is more resistant to oxidative reactions with O<sub>2</sub>.<sup>14,15,27,40</sup>

Equilibration of H<sub>ox</sub> CrHydA1 under 100% H<sub>2</sub> led to a collective shift in the νCO peaks, consistent with ligand exchange and electronic transitions at the H cluster associated with H<sub>2</sub> activation as previously described.<sup>33,41</sup> Figure 2c shows the spectrum of H<sub>2</sub>-reduced CrHydA1 with principle νCO peaks, assigned to a mixed population of reduced intermediates, observed at 1792, 1882, 1891, 1916, 1933, 1953, and 1963 cm<sup>-1</sup> (Figure 2c, red spectrum).<sup>33,41,42</sup> Additional low intensity H<sub>ox</sub>-CO peaks were seen in this sample, possibly arising from a slight amount of O<sub>2</sub> exposure during H<sub>2</sub> treatment. Exposure of H<sub>red</sub>-H<sub>2</sub> CrHydA1 to ~0.01% O<sub>2</sub> for 2 h, in the presence of


100% H<sub>2</sub> atmosphere, led to attenuation of the 1792, 1882, 1891, 1916, and 1933 cm<sup>-1</sup> peaks (Figure 2c, red vs black spectrum) accompanied by an increase in peak intensities assigned to H<sub>ox</sub> at 1804, 1940, and 1964 cm<sup>-1</sup> together with a small increase in peak intensities assigned to H<sub>ox</sub>-CO at 1969 and 2013 cm<sup>-1</sup>.

When H<sub>ox</sub> CrHydA1 was treated with NaDT (20 mM final concentration), the initial spectrum (Figure 2d, red spectrum) showed  $\nu$ CO peaks at 1861, 1882, 1891, 1916, 1961, and 1979 cm<sup>-1</sup> previously assigned to reduced intermediates.<sup>33,41,42</sup> Compared to H<sub>ox</sub> (Figure 2a), the NaDT-treated CrHydA1 showed less signal attenuation after exposure to O<sub>2</sub> (Figure 2d, red vs black spectra), with only a small loss of 2Fe subcluster signal after 2 h of exposure to ~0.05% O<sub>2</sub>. Regarding  $\nu$ CO peak intensities, the O<sub>2</sub> treatment produced new peaks at 1946 and 1969 cm<sup>-1</sup>, a slight increase in peak intensities at 1916 and 2013 cm<sup>-1</sup>, and larger increases in peak intensities at 1804 and 1940 cm<sup>-1</sup>. The increases at 1804 and 1940 cm<sup>-1</sup> are assigned to an increase in the population of H<sub>ox</sub>, and the changes at 1969 and 2013 cm<sup>-1</sup> are assigned to an increase in the population of H<sub>ox</sub>-CO. The appearance of H<sub>ox</sub> is similar to the sequence observed for O<sub>2</sub> exposure of H<sub>2</sub>-reduced CrHydA1 (see Figure S2).

**FTIR Time Series of O<sub>2</sub> Exposed H<sub>ox</sub> CrHydA1.** In order to observe O<sub>2</sub>-induced transitions in the 2Fe subcluster by FTIR on the time scales of full spectral collection (512 scans, ~8 min), CrHydA1 prepared in the H<sub>ox</sub> state (with  $\nu$ CO modes at 1804, 1940, 1964 cm<sup>-1</sup>) was incubated under a low (~0.01%) O<sub>2</sub> partial pressure at 4 °C, and FTIR spectra were collected at approximately 25 min intervals (Figure 3). Based on an O<sub>2</sub> titration series (Figure S4) we selected 0.01% O<sub>2</sub> for the time-course experiment in order to allow the time scales of oxidative transitions to match the time frame of IR sampling and data collection. Under 0.01% O<sub>2</sub>, the H<sub>ox</sub> signal gradually attenuated, which coincided with the appearance of H<sub>ox</sub>-CO with  $\nu$ CO peaks at 1809, 1963, and 2013 cm<sup>-1</sup>. A near complete loss of H<sub>ox</sub> was observed after ~200 min of O<sub>2</sub> exposure. The calculated decay rates of H<sub>ox</sub> specific  $\nu$ CO signal at 1940 cm<sup>-1</sup> directly correlated with inactivation rates (values are shown in Tables S3 and S4).

We also measured the change in the FTIR spectra of *Clostridium acetobutylicum* HydA (CaI) prepared in H<sub>ox</sub> and exposed to a ~30-fold higher concentration (~0.28%) of O<sub>2</sub>. This enzyme is ~100-fold less sensitive to O<sub>2</sub> inactivation than CrHydA1,<sup>15</sup> thus was expected to have slower kinetics of O<sub>2</sub>-induced changes in FTIR spectral features. A time-course spectrum series (Figure S5) of CaI exposed to ~0.28% O<sub>2</sub> shows a slower decay of H<sub>ox</sub> peak intensities (Tables S3 and S4) and slower appearance of H<sub>ox</sub>-CO signals, than for CrHydA1.

The amount of O<sub>2</sub>-treated H<sub>ox</sub> CrHydA1 that converted to H<sub>ox</sub>-CO was determined based on normalizing the  $\nu$ CO peak intensities in the O<sub>2</sub>-treated sample to the H<sub>ox</sub>-CO standard (Figure 2b, red spectrum). The amount of H<sub>ox</sub>-CO was estimated at ~20% after 133 min (Figure 4a) of ~0.01% O<sub>2</sub> exposure, where the rest of the signal loss is likely due to complete degradation of the 2Fe subcluster, which is observed at 253 min (Figure 4b). The O<sub>2</sub>-induced H<sub>ox</sub>-CO signal appeared simultaneously with the loss of H<sub>ox</sub> and slowly decreased in intensity after 133 min (Figure 3). After a longer period of exposure, the loss of H<sub>ox</sub>-CO was accompanied by the appearance of new  $\nu$ CO peaks at 1825, 1925, and 2025 cm<sup>-1</sup> (Figure 4b).




**Figure 4.** FTIR spectra of H<sub>ox</sub> CrHydA1 after long-term exposure to 0.01% O<sub>2</sub>, pH 8, 277 K. Scans taken at (a) 133 and (b) 253 min, after exposure to O<sub>2</sub>. Wavenumber coloring is as described in Figure 2.

The putative  $\nu$ CO bands at 1825, 1925, and 2025 cm<sup>-1</sup> might arise from oxygenation of a bridging thiolate, which was observed to induce a 6–19 cm<sup>-1</sup> upshift of the  $\nu$ CO IR bands.<sup>43</sup> It is possible that O<sub>2</sub> or a byproduct of O<sub>2</sub> led to a similar effect on CrHydA1  $\nu$ CO bands (see Figure 4a,b).<sup>43</sup> In depth DFT calculations on O<sub>2</sub> binding to the H cluster propose reaction pathways that include both oxygenation of Fe<sub>d</sub> and oxidation of 2Fe.<sup>20,21,23,44,45</sup> In this case, the resulting oxidation of the 2Fe subcluster would be expected to cause an upshift in the  $\nu$ CO bands, again consistent with the observed upshifts in CrHydA1 H<sub>ox</sub> spectrum after O<sub>2</sub> exposure.

**UV-vis of O<sub>2</sub> Exposed CrHydA1.** UV-vis spectroscopy was employed to monitor the [4Fe-4S] cluster during O<sub>2</sub> exposure. The absorption spectra of holo-CrHydA1, CrHydA1 expressed in the absence of HydE, HydF, and HydG and lacking the 2Fe subcluster (CrHydA1<sup>ΔEFG</sup>), and the O<sub>2</sub> inactivated CrHydA1 all showed a broad 415–420 nm absorbance feature associated with S → Fe charge-transfer bands of FeS clusters. CrHydA1<sup>ΔEFG</sup> contains only a [4Fe-4S] subcluster inserted by *E. coli*'s FeS cluster assembly machinery.<sup>46,47</sup>

Inactivation of CrHydA1 by exposure to ~0.001% and 17% O<sub>2</sub> for 2 h was monitored by H<sub>2</sub> evolution activity and UV-vis spectroscopy. The initial activity was 500 μmol min<sup>-1</sup> mg<sup>-1</sup>, which declined after the 2 h 0.001% O<sub>2</sub> treatment to 12 μmol min<sup>-1</sup> mg<sup>-1</sup>. CrHydA1 that was not exposed to O<sub>2</sub> did not show a decrease in specific activity nor any change in the UV-vis spectra. The blue trace in Figure 5b,c is the starting spectrum of holo-CrHydA1, and the black trace is after 2 h incubation with 0.001% O<sub>2</sub>, the brown trace is after 2 h incubation with 17% O<sub>2</sub>. The difference spectra between holo-CrHydA1 (Figure 5b,c, blue trace) and O<sub>2</sub> inactivated CrHydA1 (Figure 5b,c, black and orange traces) did not reveal significant differences (data not shown), suggesting that most of the S → Fe charge-transfer absorption is maintained after O<sub>2</sub> inactivation. This result is consistent with stability of the [4Fe-4S] cluster against O<sub>2</sub> damage. CrHydA1 that was exposed to large amounts of O<sub>2</sub> (3 atm of 100% O<sub>2</sub> for 3 h) exhibited



**Figure 5.** Crystal structure and UV-vis of  $O_2$  inactivated CrHydA1. (a) Electron density map contoured at  $2\sigma$  showing extra electron density in the H cluster environment including oxidized Cys 169. The conserved [FeFe]-hydrogenase motifs are depicted below the ribbon diagram with Cys 169 (starred). Reactions with  $O_2$  were conducted at pH 8, 298 K. (b) The full spectrum of reduced immature CrHydA1 $^{\Delta EFG}$  (red line), and of holo-CrHydA1 (blue line) after inactivation with 0.001%  $O_2$  2 h (black line), after inactivation with 17%  $O_2$  2 h (dark-red line), or with 3 atm of 100%  $O_2$  for 3 h (green line). (c) A close-up view of the 350–550 nm region. Reactions with  $O_2$  were conducted at pH 8, 277 K.

significant decay in the peak at 420 nm (Figure 5b,c, green trace) consistent with the loss of S  $\rightarrow$  Fe charge-transfer bands of FeS clusters.

**In-vitro Activation of  $O_2$  Inactivated CrHydA1.** CrHydA1 that had been  $O_2$  inactivated could be *in vitro* reactivated with HydF $^{EG}$  (Figure S7) to  $\sim$ 80% of the as-purified activity level. The remaining population of enzyme that could not be re-activated was likely degradation products that do not have an intact [4Fe-4S] cluster.<sup>48</sup> This data suggests there is a significant population of enzyme ( $\sim$ 80%) containing intact [4Fe-4S] after  $O_2$  exposure. It had been previously shown that HydF $^{EG}$  is sufficient for activating CrHydA1 $^{\Delta EFG}$ <sup>32</sup> and that activation of CrHydA1 $^{\Delta EFG}$  requires the assembly of a preformed [4Fe-4S] cluster.<sup>46</sup>

**Structural Characterization of  $O_2$  Inactivated CrHydA1.** CrHydA1 inactivated by  $O_2$  readily crystallized, and the structure was determined to  $\sim$ 2.3 Å resolution. The resulting structure was very similar to the previously characterized structure of purified CrHydA1 expressed in the absence of [FeFe]-hydrogenase maturases HydE, HydF, and HydG with an overall root-mean-squared deviation between the two structures of 0.29 Å.<sup>46</sup> The structure revealed a vacant 2Fe subcluster site and an intact [4Fe-4S] subcluster (Figure 5a) and an open channel leading from the surface to the site left vacant in absence of the 2Fe subcluster. This suggests that the  $O_2$  inactivated CrHydA1 is the appropriate conformation and is consistent with the observation that  $O_2$  inactivated CrHydA1 can be reactivated by the H cluster maturation machinery. In addition, the structure revealed three Cys residues (amino acids 88, 169, and 238) to have additional electron density around the sulfur atoms, which can be modeled and refined suggesting sulfenic acid at position Cys 169 (which functions in proton-transfer to the H-cluster).<sup>49,50</sup> Sulfenic acid was modeled at position 169 in two conformations at 0.7 and 0.3 relative occupancies. The relative B factors of oxygen were in line with those of the adjacent sulfur in both conformations indicating complete oxidation of Cys 169. Similar electron density was observed for surface localized Cys 238 and Cys 88 also presumed to be oxidized. No modifications of the four Cys

residues that function to coordinate the H cluster (Cys 170, 225, 417, and 421) were detected. Due to the functional importance of Cys 169,<sup>49,50</sup> mass spectrometry (MS) analysis was used to confirm the presence of sulfenic acid at the Cys 169 position (Figure S6).

## DISCUSSION

FTIR analysis of CrHydA1 incubated in the presence of  $\sim$ 0.01%  $O_2$  and in the absence of exogenously added reducing agents exhibited attenuation of the  $H_{ox}$  state. The attenuation of the  $H_{ox}$  signal tracked closely with the loss of enzyme activity. A detectable level of  $H_{ox}$ -CO signal appeared with the loss of the  $H_{ox}$  signal, suggesting degradation of the 2Fe subcluster liberates CO that in turn binds to the remaining intact H clusters, generating  $H_{ox}$ -CO.

The changes that occur when CrHydA1 was exposed to  $O_2$  appear to occur to a greater extent and at a higher rate when poised in the  $H_{ox}$  state. Enzymes poised in  $H_{ox}$ -CO,  $H_{red}$ - $H_2$ , and  $H_{red}$ -NaDT were less prone to  $O_2$ -dependent decay. The data show that an H cluster that is presumably coordinately saturated with an occupied  $Fe_4$  ligand exchangeable site is more resistant to  $O_2$  damage consistent with this site as the initial site of  $O_2$  binding and attack along the pathway of H cluster degradation.<sup>13–15,21,22,26,27</sup> The addition of CO had the greatest protective effect with no observable decay of  $H_{ox}$ -CO up to 24.7%  $O_2$  (Figure S1) over 2 h of exposure, consistent with previous electrochemical observations.<sup>14,15,27</sup> The reduced samples showed a clear transition to  $H_{ox}$  ( $1940\text{ cm}^{-1}$   $\nu$ CO) prior to signal decay and H cluster degradation. Subsequently, similar degradation products are observed in the NaDT- and  $H_2$ -treated CrHydA1 samples as were observed with  $H_{ox}$  samples, with the transient appearance of  $H_{ox}$ -CO-specific FTIR features.

The  $O_2$  inactivated CrHydA1 was capable of being reactivated by the addition of HydF $^{EG}$  suggesting that the inactivated enzyme has a damaged or absent 2Fe subcluster. Further, as described above, both UV-vis spectroscopy and structural characterization indicated the presence of an intact [4Fe-4S] subcluster that was stable long after activity

attenuated. Interestingly, the X-ray crystal structure and UV-vis of O<sub>2</sub> inactivated CrHydA1 strongly resembled CrHydA1 expressed in the absence of maturases (CrHydA1<sup>ΔEFG</sup>). Previous studies probing H cluster degradation using comparatively higher concentrations of O<sub>2</sub> either with<sup>28</sup> or without<sup>27</sup> NaDT proposed that the degradation of the [4Fe-4S] subcluster preceded 2Fe subcluster degradation, whereby ROS was generated by O<sub>2</sub> binding and reaction at the 2Fe subcluster. Under the conditions of our study in which CrHydA1 was exposed to O<sub>2</sub> in the absence of NaDT, the [4Fe-4S] subcluster seems fairly resistant to degradation (see Figure 5). We do however observe evidence for the oxidation of the non-coordinating active site Cys (Cys 169) perhaps through the formation of ROS. These results further support the formation of ROS species in the pathway of O<sub>2</sub> inactivation and highlight the apparent resilience of the [4Fe-4S] subcluster to O<sub>2</sub> initiated degradation relative to the 2Fe subcluster. Exposure of either the O<sub>2</sub> degradation intermediate observed here or CrHydA1<sup>ΔEFG</sup> to high concentrations of O<sub>2</sub> resulted in the eventual destruction of the [4Fe-4S] subcluster, as evidenced by reduction and eventual loss of the S → Fe charge-transfer bands at ~420 nm.

Thus, based on the experimental evidence presented here, we propose that the mechanism of O<sub>2</sub> attack on CrHydA1 first involves degradation of the more labile 2Fe subcluster, followed by attack on the more robust [4Fe-4S] subcluster.

## CONCLUSION

The inactivation of [FeFe]-hydrogenase by O<sub>2</sub> is defined by steps that involve the diffusion of gases into close proximity of the catalytic site, followed by redox and chemical reactions of O<sub>2</sub> with the H cluster. Our results are consistent with theoretical models<sup>21</sup> that the latter process leads to oxidative breakdown of the 2Fe subcluster and eventual formation of a stable [4Fe-4S] subcluster product with a vacant 2Fe subcluster site. This product was capable of being reactivated by 2Fe subcluster-specific maturation machinery. Long-term and/or high-concentration O<sub>2</sub> exposure is required for oxidative damage of the [4Fe-4S] subcluster and complete H cluster degradation.

## ASSOCIATED CONTENT

### Supporting Information

Additional FTIR spectra of O<sub>2</sub>-treated CaI and O<sub>2</sub>-treatment of H<sub>ox</sub>, H<sub>red</sub>-DT, and CO-inhibited CrHydA1, CrHydA1 activity, and HydF titration data, peptide map and MS data for Cys169, experimental conditions summary table, and crystallographic data collection and refinement statistics for O<sub>2</sub>-exposed CrHydA1. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## AUTHOR INFORMATION

### Corresponding Authors

\*paul.king@nrel.gov

\*john.peters@chemistry.montana.edu

### Author Contributions

§These authors contributed equally.

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

J.W.P. thanks the Air Force Office of Scientific Research grant 574 FA-9550-11-1-0218 for supporting work on the mechanism of oxygen sensitivity. M.W.R., D.W.M., and P.W.K. gratefully acknowledge funding support for CrHydA1 and CaI preparation and FTIR spectra measurements from the U.S. Department of Energy, Office of Science, Basic Energy Sciences, Division of Chemical Sciences, Geosciences, and Biosciences and support of the U.S. Department of Energy under contract no. DE-AC36-08-GO28308 with the National Renewable Energy Laboratory. The work on reactivation of damaged CrHydA1 with purified HydF was supported by the U.S. Department of Energy grant DE-FG02-10ER16194 (to J.B.B. and J.W.P.). Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under contract no. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393). The mass spectrometry facility at MSU receives funding from the Murdock Charitable Trust and NIH 5P20RR02437 of the Cobre program. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH. Atomic coordinates were deposited in the PDB (code, 4ROV).

## REFERENCES

- (1) Vignais, P. M.; Billoud, B. *Chem. Rev.* **2007**, *107* (10), 4206–4272.
- (2) McKinlay, J. B.; Harwood, C. S. *Curr. Opin. Biotechnol.* **2010**, *21* (3), 244–251.
- (3) Turner, J.; Sverdrup, G.; Mann, M. K.; Maness, P.-C.; Kroposki, B.; Ghirardi, M.; Evans, R. J.; Blake, D. *Int. J. Energy Res.* **2008**, *32* (5), 379–407.
- (4) Nicolet, Y.; Piras, C.; Legrand, P.; Hatchikian, C. E.; Fontecilla-Camps, J. C. *Structure* **1999**, *7* (1), 13–23.
- (5) Peters, J. W.; Lanzilotta, W. N.; Lemon, B. J.; Seefeldt, L. C. *Science* **1998**, *282* (5395), 1853–1858.
- (6) Pandey, A. S.; Harris, T. V.; Giles, L. J.; Peters, J. W.; Szilagy, R. K. *J. Am. Chem. Soc.* **2008**, *130* (13), 4533–4540.
- (7) Silakov, A.; Wenk, B.; Reijerse, E.; Lubitz, W. *Phys. Chem. Chem. Phys.* **2009**, *11* (31), 6592–6599.
- (8) Berggren, G.; Adamska, A.; Lambert, C.; Simmons, T. R.; Esselborn, J.; Atta, M.; Gambarelli, S.; Mouesca, J. M.; Reijerse, E.; Lubitz, W.; Happe, T.; Artero, V.; Fontecave, M. *Nature* **2013**, *499* (7456), 66–69.
- (9) Ghirardi, M. L.; Posewitz, M. C.; Maness, P.-C.; Dubini, A.; Yu, J.; Seibert, M. *Annu. Rev. Plant Biol.* **2007**, *58* (1), 71–91.
- (10) Melis, A.; Seibert, M.; Happe, T. *Photosynth. Res.* **2004**, *82* (3), 277–288.
- (11) Erbes, D. L.; King, D.; Gibbs, M. *Plant Physiol.* **1979**, *63* (6), 1138–1142.
- (12) Cohen, J.; Kim, K.; Posewitz, M.; Ghirardi, M. L.; Schulten, K.; Seibert, M.; King, P. *Biochem. Soc. Trans.* **2005**, *33* (Pt1), 80–82.
- (13) Liebgott, P.-P.; Leroux, F.; Burlat, B.; Dementin, S.; Baffert, C.; Lautier, T.; Fourmond, V.; Ceccaldi, P.; Cavazza, C.; Meynial-Salles, I.; Soucaille, P.; Fontecilla-Camps, J. C.; Guigliarelli, B.; Bertrand, P.; Rousset, M.; Léger, C. *Nat. Chem. Biol.* **2010**, *6* (1), 63–70.
- (14) Baffert, C.; Demuez, M.; Courmac, L.; Burlat, B.; Guigliarelli, B.; Bertrand, P.; Girbal, L.; Léger, C. *Angew. Chem., Int. Ed.* **2008**, *47* (11), 2052–2054.
- (15) Goldet, G.; Brandmayr, C.; Stripp, S. T.; Happe, T.; Cavazza, C.; Fontecilla-Camps, J. C.; Armstrong, F. A. *J. Am. Chem. Soc.* **2009**, *131* (41), 14979–14989.

- (16) Vincent, K. A.; Parkin, A.; Lenz, O.; Albracht, S. P. J.; Fontecilla-Camps, J. C.; Cammack, R.; Friedrich, B.; Armstrong, F. A. *J. Am. Chem. Soc.* **2005**, *127* (51), 18179–18189.
- (17) Cohen, J.; Kim, K.; King, P. W.; Seibert, M.; Schulten, K. *Structure* **2005**, *13* (9), 1321–1329.
- (18) Lautier, T.; Ezanno, P.; Baffert, C.; Fourmond, V.; Cournac, L.; Fontecilla-Camps, J. C.; Soucaille, P.; Bertrand, P.; Meynial-Salles, I.; Leger, C. *Faraday Discuss.* **2011**, *148* (0), 385–407.
- (19) Nicolet, Y.; Cavazza, C.; Fontecilla-Camps, J. C. *J. Inorg. Biochem.* **2002**, *91* (1), 1–8.
- (20) Bruska, M. K.; Stiebritz, M. T.; Reiher, M. *J. Am. Chem. Soc.* **2011**, *133* (50), 20588–20603.
- (21) Stiebritz, M. T.; Reiher, M. *Chem. Sci.* **2012**, *3* (6), 1739–1751.
- (22) Kubas, A.; De Sancho, D.; Best, R. B.; Blumberger, J. *Angew. Chem., Int. Ed.* **2014**, *126* (16), 4165–4168.
- (23) Finkelman, A. R.; Stiebritz, M. T.; Reiher, M. *Inorg. Chem.* **2014**, *53* (22), 11890–11902.
- (24) Hong, G.; Pachter, R. *ACS Chem. Biol.* **2012**, *7* (7), 1268–1275.
- (25) Dey, S.; Rana, A.; Crouthers, D.; Mondal, B.; Das, P. K.; Darensbourg, M. Y.; Dey, A. *J. Am. Chem. Soc.* **2014**, *136* (25), 8847–8850.
- (26) Fourmond, V.; Greco, C.; Sybirna, K.; Baffert, C.; Wang, P.-H.; Ezanno, P.; Montefiori, M.; Bruschi, M.; Meynial-Salles, I.; Soucaille, P.; Blumberger, J.; Bottin, H.; De Gioia, L.; Léger, C. *Nat. Chem.* **2014**, *6* (4), 336–342.
- (27) Stripp, S. T.; Goldet, G.; Brandmayr, C.; Sanganas, O.; Vincent, K. A.; Haumann, M.; Armstrong, F. A.; Happe, T. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106* (41), 17331–17336.
- (28) Lambertz, C.; Leidel, N.; Havelius, K. G. V.; Noth, J.; Chernev, P.; Winkler, M.; Happe, T.; Haumann, M. *J. Biol. Chem.* **2011**, *286*, 40614–40623.
- (29) Greco, C.; Fourmond, V.; Baffert, C.; Wang, P.-h.; Dementin, S.; Bertrand, P.; Bruschi, M.; Blumberger, J.; de Gioia, L.; Leger, C. *Energy Environ. Sci.* **2014**, *7* (11), 3543–3573.
- (30) King, P. W.; Posewitz, M. C.; Ghirardi, M. L.; Seibert, M. *J. Bacteriol.* **2006**, *188* (6), 2163–2172.
- (31) Yacoby, I.; Tegler, L. T.; Pochekailov, S.; Zhang, S.; King, P. W. *PLoS One* **2012**, *7* (4), e35886.
- (32) McGlynn, S. E.; Shepard, E. M.; Winslow, M. A.; Naumov, A. V.; Duschene, K. S.; Posewitz, M. C.; Broderick, W. E.; Broderick, J. B.; Peters, J. W. *FEBS Lett.* **2008**, *582* (15), 2183–2187.
- (33) Mulder, D. W.; Ratzloff, M. W.; Shepard, E. M.; Byer, A. S.; Noone, S. M.; Peters, J. W.; Broderick, J. B.; King, P. W. *J. Am. Chem. Soc.* **2013**, *135* (18), 6921–6929.
- (34) Kabsch, W. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66* (2), 125–132.
- (35) Evans, P. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2006**, *62* (1), 72–82.
- (36) Vagin, A.; Teplyakov, A. *J. Appl. Crystallogr.* **1997**, *30* (6), 1022–1025.
- (37) Pierik, A. J.; Hulstein, M.; Hagen, W. R.; Albracht, S. P. J. *Eur. J. Biochem.* **1998**, *258* (2), 572–578.
- (38) Roseboom, W.; De Lacey, A.; Fernandez, V.; Hatchikian, E. C.; Albracht, S. J. *J. Biol. Inorg. Chem.* **2006**, *11* (1), 102–118.
- (39) Chen, Z. J.; Lemon, B. J.; Huang, S.; Swartz, D. J.; Peters, J. W.; Bagley, K. A. *Biochemistry* **2002**, *41* (6), 2036–2043.
- (40) Bennett, B.; Lemon, B. J.; Peters, J. W. *Biochemistry* **2000**, *39* (25), 7455–7460.
- (41) Adamska, A.; Silakov, A.; Lambertz, C.; Rüdiger, O.; Happe, T.; Reijerse, E.; Lubitz, W. *Angew. Chem., Int. Ed.* **2012**, *51* (46), 11458–11462.
- (42) Silakov, A.; Kamp, C.; Reijerse, E.; Happe, T.; Lubitz, W. *Biochemistry* **2009**, *48* (33), 7780–7786.
- (43) Liu, T.; Li, B.; Singleton, M. L.; Hall, M. B.; Darensbourg, M. Y. *J. Am. Chem. Soc.* **2009**, *131* (23), 8296–8307.
- (44) Stiebritz, M. T.; Reiher, M. *Inorg. Chem.* **2009**, *48* (15), 7127–7140.
- (45) Stiebritz, M. T.; Finkelman, A. R.; Reiher, M. *Eur. J. Inorg. Chem.* **2011**, *2011* (7), 1163–1171.
- (46) Mulder, D. W.; Ortillo, D. O.; Gardenghi, D. J.; Naumov, A. V.; Ruebush, S. S.; Szilagy, R. K.; Huynh, B.; Broderick, J. B.; Peters, J. W. *Biochemistry* **2009**, *48* (26), 6240–6248.
- (47) Mulder, D. W.; Boyd, E. S.; Sarma, R.; Lange, R. K.; Endrizzi, J. A.; Broderick, J. B.; Peters, J. W. *Nature* **2010**, *465* (7295), 248–251.
- (48) Nicolet, Y.; Rohac, R.; Martin, L.; Fontecilla-Camps, J. C. *Proc. Natl. Acad. Sci. U.S.A.* **2013**, *110* (18), 7188–7192.
- (49) Cornish, A. J.; Gärtner, K.; Yang, H.; Peters, J. W.; Hegg, E. L. *J. Biol. Inorg. Chem.* **2011**, *286* (44), 38341–38347.
- (50) Mulder, D. W.; Ratzloff, M. W.; Bruschi, M.; Greco, C.; Koonce, E.; Peters, J. W.; King, P. W. *J. Am. Chem. Soc.* **2014**, *136* (43), 15394–15402.